CeriBell (CBLL) Q2 FY26 earnings call

CeriBell reported strong Q2 FY26 results with accelerating revenue growth and record gross margins, fueled by robust same-store performance and account expansion. The company secured FDA clearances for new algorithms and a next-gen hardware platform, while its Delirium Monitoring Solution received favorable NTAP and is slated for commercial launch this year. Management is focused on achieving cash flow break-even and leveraging its expanding product portfolio for sustained long-term growth.